Research location
San Jose
California, United States
Research activity in San Jose
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 472 trials and 492 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in San Jose
472 linked trials · page 1 of 10A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe AsthmaNCT07532265 · 2026-07-16 · 1 site observation
RECRUITING
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNCT07446439 · 2026-03-27 · 1 site observation
RECRUITING
Distance-Based Exercise to Preserve Function and Prevent DisabilityNCT07059884 · 2026-02-11 · 1 site observation
RECRUITING
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in AdultsNCT07301255 · 2026-01-09 · 1 site observation
RECRUITING
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT07115329 · 2026-01-05 · 1 site observation
RECRUITING
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialNCT06931340 · 2025-12-01 · 1 site observation
RECRUITING
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531 · 2025-11-25 · 1 site observation
RECRUITING
A Study of Modified Release RTN-001 In Patients With Uncontrolled HypertensionNCT07142356 · 2025-10-31 · 1 site observation
RECRUITING
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)NCT07101094 · 2025-09-22 · 1 site observation
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 2 site observations
RECRUITING
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT07196501 · 2025-08-18 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28 · 1 site observation
RECRUITING
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581 · 2025-05-20 · 1 site observation
RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401 · 2025-04-16 · 1 site observation
RECRUITING
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · 2025-04-01 · 1 site observation
RECRUITING
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263 · 2025-03-26 · 1 site observation
RECRUITING
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044 · 2025-03-03 · 1 site observation
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation
RECRUITING
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)NCT06633016 · 2024-09-20 · 1 site observation
RECRUITING
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsNCT06559306 · 2024-07-25 · 1 site observation
RECRUITING
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · 2024-07-19 · 1 site observation
RECRUITING
Safer Aging With Diabetes MonitoringNCT06296485 · 2024-05-01 · 1 site observation
RECRUITING
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 1 site observation
RECRUITING
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate TreatmentNCT06235697 · 2024-04-25 · 1 site observation
RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213 · 2023-12-14 · 1 site observation
RECRUITING
Personalized Accelerated ChEmoRadiation (PACER) for Lung CancerNCT06080061 · 2023-10-25 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 2 site observations
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 2 site observations
RECRUITING
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05 · 1 site observation
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 2 site observations
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 1 site observation
RECRUITING
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerNCT03678025 · 2018-09-24 · 1 site observation
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01 · 1 site observation
RECRUITING
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.NCT06458907 · 2026-08-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678 · 2026-01-22 · 1 site observation
COMPLETED
DSLT in Normal Tension Glaucoma (NTG) Asian EyesNCT07300852 · 2026-01-01 · 1 site observation
NOT_YET_RECRUITING
Clinical Outcomes of a Digital Mental Health Intervention for Moderate/Severe Depression and AnxietyNCT07081061 · 2025-10-06 · 1 site observation
COMPLETED
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 · 2025-09-02 · 1 site observation
ENROLLING_BY_INVITATION
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe AsthmaNCT07120503 · 2025-07-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453 · 2025-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901 · 2025-03-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's DiseaseNCT06822517 · 2025-03-05 · 1 site observation
TERMINATED
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 2 site observations
SUSPENDED
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With AsthmaNCT06644924 · 2025-02-10 · 1 site observation
COMPLETED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.